125I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma

Figure 3 Therapeutic efficacy of ¹²⁵I-bFGF mAb in mice with H22 hepatocellular carcinoma. A: Tumor volume of H22 HCC; B: Tumor weight of H22 HCC; C: Tumor inhibition ratios of experimental groups; ^aP < 0.05, ¹²⁵I-bFGF mAb group vs other groups (control, ¹²⁵I, bFGF mAb and ¹²⁵I plus bFGF mAb). HCC: Hepatocellular carcinoma.